Masimo (MASI) Stock
Medical device maker focused on patient monitoring systems. Here's the price, business snapshot, and what's worth knowing about Masimo in September 2026.
Masimo Corporation (ticker: MASI) develops non‑invasive monitoring technologies and patient‑monitoring systems used in hospitals, ambulatory settings and by consumers. Its product range includes advanced pulse oximetry sensors, monitoring platforms and software that aggregate physiological data for clinicians, alongside newer efforts in wearable and home monitoring. Revenue comes from device sales, sensors and recurring consumables, and software services; the company emphasises R&D and intellectual property as competitive assets. With a market capitalisation around $8.06 billion, Masimo sits among mid‑cap medical‑technology names and faces competition from larger equipment makers and emerging digital-health firms. Key considerations for investors include sensitivity to hospital procurement cycles, regulatory approvals, and potential litigation or patent disputes — all of which can affect results. Masimo’s business can offer exposure to healthcare’s structural demand for monitoring, but performance may be volatile; this summary is educational only, not personalised investment advice, and prospective investors should consider risk tolerance and seek professional guidance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Masimo's stock, expecting its value to rise to $183.75.
Financial Health
Masimo is showing strong revenue and cash generation, indicating good overall financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Non‑invasive monitoring
Masimo’s core sensors and monitors address steady clinical demand for safer, continuous vital‑sign tracking — though sales can fluctuate with hospital procurement cycles.
Hospital to home
Growing interest in remote and home monitoring could expand Masimo’s addressable market, while reimbursement and regulatory pathways remain key variables.
Technology differentiator
R&D and intellectual property underpin Masimo’s product positioning, but patent disputes and competition are ongoing considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
